AFP联合GGT/AST对HBV相关肝细胞癌的诊断价值
DOI: 10.3969/j.issn.1001-5256.2021.09.021
利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:蔡馨负责课题设计,资料分析,撰写论文; 陈娟娟、汤冬玲参与收集数据、论文修改; 张平安负责拟定写作思路,指导撰写文章并最后定稿。
Value of alpha-fetoprotein combined with gamma-glutamyl transpeptidase/aspartate aminotransferase ratio in diagnosis of HBV-associated hepatocellular carcinoma
-
摘要:
目的 探讨AFP联合GGT/AST在HBV相关肝细胞癌(HCC)中的临床诊断价值。 方法 选取2019年1月15日—6月15日于武汉大学人民医院诊治的慢性乙型肝炎患者(CHB组)、乙型肝炎肝硬化患者(LC组)、HBV相关HCC患者(HCC组)和健康体检者(HC组)共352例,其中HC组86例,CHB组68例,LC组69例,HCC组129例,回顾性分析所有研究对象血清学检测数据。正态分布计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验。偏态分布计量资料多组间比较采用Kruskal-Wallis H检验,进一步两两比较采用Nemenyi法检验。通过二元logistic回归分析计算出预测变量,并绘制AFP、GGT/AST以及预测变量单独或联合检测的受试者工作特征曲线(ROC曲线),计算曲线下面积(AUC)及敏感度、特异度,采用Z检验对AUC进行比较。 结果 HCC组GGT/AST和AFP水平均显著高于其他组(P值均<0.05)。ROC曲线分析结果显示,在HCC组与LC组、HCC组与HC组+CHB组+LC组、HCC组与CHB组+LC组中,AFP与GGT/AST联合诊断的AUC均明显高于AFP单独诊断的AUC(Z值分别为2.684、2.241、2.415,P值分别为0.007、0.025、0.016)。 结论 AFP联合GGT/AST可提高HBV相关HCC的临床诊断性能,具有一定诊断价值。 -
关键词:
- 乙型肝炎病毒 /
- 癌, 肝细胞 /
- 甲胎蛋白类 /
- γ-谷氨酰转移酶 /
- 天冬氨酸氨基转移酶类
Abstract:Objective To investigate the clinical value of alpha-fetoprotein (AFP) combined with gamma-glutamyl transpeptidase (GGT)/aspartate aminotransferase (AST) ratio in the diagnosis of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Methods A total of 352 subjects who received treatment or underwent physical examination in Renmin Hospital of Wuhan University from January 15 to June 15, 2020, were enrolled, among whom there were 86 healthy controls (HC group), 68 patients with chronic hepatitis B (CHB group), 69 patients with liver cirrhosis (LC group), and 129 patients with HCC (HCC group), and a retrospective analysis was performed for the serological test results of all subjects. An analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between multiple groups, and the Nemenyi method was used for further comparison between two groups. A binary logistic regression analysis was used to calculate predictor variables; a receiver operating characteristic (ROC) curve was plotted for AFP, GGT/AST, and the predictor variables used alone or in combination, and the area under the ROC curve (AUC), sensitivity, and specificity were calculated; the Z test was used for comparison of AUC. Results The HCC group had significantly higher GGT/AST ratio and AFP than the other groups (all P < 0.05). The ROC curve analysis showed that AFP combined with GGT/AST ratio had a significantly higher AUC than AFP alone in the HCC group vs the LC group, the HCC group vs the HC+CHB+LC groups, and the HCC group vs the CHB+LC groups (Z=2.684, 2.241, and 2.415, P=0.007, 0.025, and 0.016). Conclusion AFP combined with GGT/AST ratio can improve the clinical diagnostic performance of HBV-related HCC and thus has a certain diagnostic value. -
表 1 各组AFP、GGT、AST及GGT/AST血清学水平比较
组别 例数 AFP(ng/ml) GGT/AST GGT(U/L) AST(U/L) HC组 86 3.35(2.20~4.70) 0.98(0.71~1.36) 20.00(15.00~27.00) 21.00(18.00~24.00) CHB组 68 4.35(2.35~15.75) 0.82(0.46~1.25) 51.00(23.75~140.75)1) 61.00(34.25~125.00)1) LC组 69 8.60(2.70~54.20)1) 0.97(0.55~1.81) 69.00(27.00~113.00)1) 47.00(31.00~88.00)1) HCC组 129 157.10(9.90~6126.40)1)2)3) 2.00(1.19~3.11)1)2)3) 98.00(45.00~207.00)1)2)3) 46.00(29.00~88.00)1)2) H值 124.018 70.202 126.282 135.987 P值 <0.001 <0.001 <0.001 <0.001 注:与HC组比较,1)P<0.05;与CHB组比较,2)P<0.05;与LC组比较,3)P<0.05。 表 2 AFP与GGT/AST单独或联合检测在辅助HCC诊断中的价值
分组 标志物 AUC 95%CI 敏感度(%) 特异度(%) P值 HCC组vs CHB组 AFP 0.803 0.742~0.864 72.9 72.1 <0.05 GGT/AST 0.789 0.717~0.861 67.4 83.8 <0.05 联合 0.846 0.790~0.910 79.8 77.9 <0.05 HCC组vs LC组 AFP 0.760 0.693~0.826 55.8 84.1 <0.05 GGT/AST 0.727 0.650~0.803 90.7 46.4 <0.05 联合 0.802 0.741~0.862 48.1 97.1 <0.05 HCC组vs HC组+CHB组+LC组 AFP 0.835 0.791~0.879 86.0 68.2 <0.05 GGT/AST 0.768 0.718~0.817 67.4 74.9 <0.05 联合 0.843 0.802~0.885 73.6 78.5 <0.05 HCC组vs CHB组+LC组 AFP 0.781 0.727~0.835 55.8 85.4 <0.05 GGT/AST 0.758 0.700~0.815 67.4 77.5 <0.05 联合 0.823 0.775~0.871 81.4 66.4 <0.05 -
[1] CHEN Y, TIAN Z. HBV-induced immune imbalance in the development of HCC[J]. Front Immunol, 2019, 10: 2048. DOI: 10.3389/fimmu.2019.02048. [2] ORTEGA-PRIETO AM, DORNER M. Immune evasion strategies during chronic hepatitis B and C virus infection[J]. Vaccines (Basel), 2017, 5(3): 24. DOI: 10.3390/vaccines5030024. [3] TAROCCHI M, POLVANI S, MARRONCINI G, et al. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis[J]. World J Gastroenterol, 2014, 20(33): 11630-11640. DOI: 10.3748/wjg.v20.i33.11630. [4] AFFO S, YU LX, SCHWABE RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer[J]. Annu Rev Pathol, 2017, 12: 153-186. DOI: 10.1146/annurev-pathol-052016-100322. [5] DIMITROULIS D, DAMASKOS C, VALSAMI S, et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world[J]. World J Gastroenterol, 2017, 23(29): 5282-5294. DOI: 10.3748/wjg.v23.i29.5282. [6] National Health and Family Planning Commission of the People' s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. [7] Chinese Journal of Hepatology, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma(2020 edition)[J]. J Clin Hepatol, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007.《中华肝脏病杂志》编辑委员会, 中华医学会肝病学分会肝癌学组. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007. [8] ZHENG Y, ZHU M, LI M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446. DOI: 10.1007/s00432-020-03331-6. [9] LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2): 599-603. DOI: 10.1007/s12253-019-00585-5. [10] SONG P, TOBE RG, INAGAKI Y, et al. The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011[J]. Liver Int, 2012, 32(7): 1053-1063. DOI: 10.1111/j.1478-3231.2012.02792.x. [11] GALLE PR, FOERSTER F, KUDO M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2214-2229. DOI: 10.1111/liv.14223. [12] WANG T, ZHANG KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma[J]. Front Oncol, 2020, 10: 1316. DOI: 10.3389/fonc.2020.01316. [13] GAO C, FANG L, YAO SK. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. J Clin Hepatol, 2014, 30(9): 921-925. DOI: 10.3969/j.issn.1001-5256.2014.09.021.高春, 房龙, 姚树坤. γ-谷氨酰转肽酶和甲胎蛋白表达的相关性及其在肝细胞癌诊断中的价值[J]. 临床肝胆病杂志, 2014, 30(9): 921-925. DOI: 10.3969/j.issn.1001-5256.2014.09.021. [14] XIA J, SONG P, SUN Z, et al. Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma[J]. Drug Discov Ther, 2016, 10(4): 181-187. DOI: 10.5582/ddt.2016.01052. [15] ZHOU L, WANG SB, CHEN SG, et al. Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy[J]. Clin Lab, 2018, 64(10): 1739-1747. DOI: 10.7754/Clin.Lab.2018.180532. [16] YANG JG, HE XF, HUANG B, et al. Rule of changes in serum GGT levels and GGT/ALT and AST/ALT ratios in primary hepatic carcinoma patients with different AFP levels[J]. Cancer Biomark, 2018, 21(4): 743-746. DOI: 10.3233/CBM-170088. 期刊类型引用(30)
1. 邹暾,龙文兴,周定中,周忠威,彭俊. 原发性肝癌采用肝动脉化疗栓塞术联合RFA的疗效及对血清miR-202、FHIT和P16蛋白水平的影响. 湘南学院学报(医学版). 2024(01): 27-29+78 . 百度学术
2. 余令兵. TACE中灌注吡柔比星治疗原发性肝癌的临床疗效及对免疫功能、血清肿瘤标志物水平的影响. 中国卫生工程学. 2024(02): 238-240+243 . 百度学术
3. 王娟,田宁,刘超,张山燕,周远. 肝动脉化疗栓塞联合靶向药物及免疫检查点抑制剂治疗中晚期肝癌的效果及对患者生存时间的影响. 大医生. 2024(07): 36-39 . 百度学术
4. 胡迎超. 血清甲胎蛋白和巨噬细胞移动抑制因子水平与原发性肝癌肝动脉化疗栓塞术患者预后的关系. 慢性病学杂志. 2023(01): 116-118 . 百度学术
5. 周菲菲,黄荣,蒋军,毛晓帆. 平均血小板体积/淋巴细胞比值对原发性肝癌SBRT治疗预后的评估价值. 西部医学. 2023(04): 563-567 . 百度学术
6. 何翠瑛,苏贞栋,陈燕红,周林荣,杨宇,姚清深. 阿帕替尼联合TACE治疗原发性肝癌复发生存的影响因素分析. 中西医结合肝病杂志. 2023(04): 298-302 . 百度学术
7. 张栋华,宋爱军,胡海军,刘朝阳. 经导管动脉化疗栓塞联合射频消融术治疗原发性肝癌患者的临床疗效. 癌症进展. 2023(08): 858-861 . 百度学术
8. 王如芹,高振东,高宗毅. 影响立体定向放射治疗原发性肝癌效果的相关因素分析. 中国基层医药. 2022(02): 285-290 . 百度学术
9. 刘爽. 基于聚焦解决模式的放松训练干预在肝癌射频消融术围术期护理中的应用效果评估. 黑龙江医学. 2022(01): 76-78 . 百度学术
10. 兰海涛,黄真婷,王小星. 超选择性肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清MMP表达的影响. 数理医药学杂志. 2022(04): 597-599 . 百度学术
11. 张雪婷,周祖邦,薛亚娥,张明华,杜学晴. TACE联合热消融与单独TACE治疗结直肠癌肝转移疗效:Meta分析. 中国介入影像与治疗学. 2022(05): 278-283 . 百度学术
12. 杜炜玮,段铮,胡斌. 经皮RFA治疗原发性肝癌的效果及对血清TGF-β1、EGR2水平的影响. 分子诊断与治疗杂志. 2022(04): 635-638 . 百度学术
13. 武文华,冯秦辉,蔡芝芳,贾晓黎,杨锐华,党双锁. 经导管动脉化疗栓塞术联合超声引导射频消融术治疗原发性肝癌对疗效及免疫功能的影响. 中国医师进修杂志. 2022(05): 459-464 . 百度学术
14. 王瑛,袁鹤立,赵利,张亚丽,马向明. 伴营养不良风险的原发性肝癌患者临床特征及预后因素分析. 中西医结合肝病杂志. 2022(06): 494-498 . 百度学术
15. 柯映平,叶绍光,卢舜彬. 肝动脉化疗栓塞术联合FOLFOX方案持续性动脉灌注化疗在巴塞罗那B期原发性肝癌患者中的应用效果. 中国当代医药. 2022(18): 73-76 . 百度学术
16. 张贻庆,崔贵医,杨磊,刘刚,冯世杰,王劲. 肝肿瘤切除术与射频消融术治疗原发性肝癌的疗效及其对血清AFP、CEA、CA125水平的影响. 实用癌症杂志. 2022(08): 1316-1319 . 百度学术
17. 孙玉,张洪海,袁春旺,龙江,郑加生,张永宏. C反应蛋白/白蛋白比值影响肝动脉栓塞联合微波消融治疗中期肝细胞癌的预后. 肝胆胰外科杂志. 2022(10): 587-592 . 百度学术
18. 郝晓光,李伟靖,朱丽娜,史博,艾宁,吴勇超,李智岗. 中晚期肝癌患者经导管化疗栓塞治疗后序贯射频消融手术治疗时机的选择. 介入放射学杂志. 2022(09): 908-912 . 百度学术
19. 章甜,贾思静,孙冬雪,龙奉玺,唐东昕,杨柱. 拉米夫定联合TACE治疗HBV相关性中晚期肝癌的Meta分析. 临床医学研究与实践. 2021(13): 36-41+47 . 百度学术
20. 付卫东,尚靖智. 肝动脉化疗栓塞术联合经皮射频消融术治疗中晚期肝癌的临床疗效评价. 吉林医学. 2021(05): 1095-1098 . 百度学术
21. 谷涛,于经瀛. 肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展. 协和医学杂志. 2021(03): 380-385 . 百度学术
22. 刘人杰. 索拉菲尼治疗原发性肝癌的效果及对患者血清HSP90α、VEGF水平的影响. 中国医学创新. 2021(14): 15-19 . 百度学术
23. 高磊磊,秦帅鑫,陈威,候振国. TACE联合RFA治疗中期原发性肝癌的疗效及对患者血清GP73、AFP和AFP-L3水平的影响. 临床和实验医学杂志. 2021(13): 1388-1391 . 百度学术
24. 金文彪. 肝动脉化疗栓塞联合射频消融在原发性肝癌中的价值. 中国卫生标准管理. 2021(17): 48-51 . 百度学术
25. 范隼,钟鹏,巫兆国. 经肝动脉化疗栓塞联合同步射频消融术治疗肝癌的初步临床研究. 吉林医学. 2021(10): 2389-2390 . 百度学术
26. 曹昆昆,李晓伟,付志刚,翟健,曲增强,丁宁. 微波消融同步联合经导管动脉化疗栓塞治疗膈下肝细胞癌. 中国介入影像与治疗学. 2021(11): 659-662 . 百度学术
27. 卢毅,周任. 肝动脉化疗栓塞联合射频消融治疗原发性小肝癌的临床效果及对患者免疫功能的影响. 广西医学. 2021(18): 2161-2165 . 百度学术
28. 何勇. 肝动脉介入化疗栓塞术联合阿帕替尼在晚期肝癌中的应用. 临床医药实践. 2020(03): 181-183 . 百度学术
29. 徐蓉,华忠. 肝硬化并发原发性肝癌的流行病学特征、危险因素及相关预防干预对策研究. 中西医结合肝病杂志. 2020(04): 357-359+366 . 百度学术
30. 刘峥嵘,俞巍. 肝动脉化疗栓塞术和肝动脉栓塞术治疗肝细胞癌的疗效. 血管与腔内血管外科杂志. 2019(02): 139-143 . 百度学术
其他类型引用(2)
-